Vanguard Information Technology ETF
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
286% more call options, than puts
Call options by funds: $502M | Put options by funds: $130M
92% more first-time investments, than exits
New positions opened: 136 | Existing positions closed: 71
3% more funds holding
Funds holding: 1,502 [Q2] → 1,543 (+41) [Q3]
9% more repeat investments, than reductions
Existing positions increased: 536 | Existing positions reduced: 493
0% more capital invested
Capital invested by funds: $30.9B [Q2] → $31B (+$66.2M) [Q3]
3.37% less ownership
Funds ownership: 42.83% [Q2] → 39.46% (-3.37%) [Q3]
12% less funds holding in top 10
Funds holding in top 10: 104 [Q2] → 92 (-12) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for VGT.
Financial journalist opinion
Based on 14 articles about VGT published over the past 30 days
Positive
The Motley Fool
1 day ago
Looking to Build a $1 Million Portfolio? 3 Vanguard ETFs to Buy in 2025 and Hold Forever
Building a portfolio worth $1 million or more isn't easy, but the right investments can get you there with enough time and consistency.
Neutral
ETF Trends
3 days ago
Earnings Season: Big Roster of Tech Results Ahead
Earnings season is in full swing. This first round right out of the gate may well set the tone for markets in 2025.
Positive
The Motley Fool
4 days ago
Prediction: This Spectacular Vanguard ETF Will Crush the S&P 500 Again in 2025
The S&P 500 (^GSPC 0.88%) delivered a return of 23% in 2024, which was more than double its average annual gain dating back to when it was established in 1957. However, had you invested in the Vanguard Information Technology ETF (VGT 0.82%) instead, you would have earned a return of 32% for the year.
Neutral
24/7 Wall Street
4 days ago
VGT vs. QQQ: Which ETF Should You Buy?
ETFs are one of our favorite investment instruments. They provide exposure to a large swath of stocks, allowing you to quickly diversify your portfolio with a single purchase.
Positive
Seeking Alpha
5 days ago
VGT: The Only One To Hold
The technology sector, despite slowing earnings growth, remains attractive due to solid future earnings expectations and AI potential, with Vanguard Information Technology Index Fund ETF Shares (VGT) being a top choice for exposure. With nearly $100 billion in assets, VGT offers broad exposure to tech stocks, including small and mid-caps, and has a low expense ratio of 0.1%. VGT's top holdings are concentrated, but that is a feature in similar funds like XLK and IYW.
Neutral
24/7 Wall Street
6 days ago
VGT vs VOO: Which Vanguard ETF Is the Better Buy Today?
Vanguard is one of the gold standards when it comes to low-cost exchange-traded fund (ETF) options.
Positive
The Motley Fool
6 days ago
3 Vanguard ETFs to Buy With $2,000 and Hold Forever
If you're looking for a more passive approach to investing but don't want to sacrifice your potential gains, there's an obvious solution -- exchange-traded funds, or ETFs. These of course are pre-selected baskets of stocks bought and sold as a group.
Positive
The Motley Fool
2 weeks ago
1 Vanguard Index Fund to Buy Before It Soars on AI Tailwinds in 2025, According to a Wall Street Analyst
The S&P 500 entered its current bull market in October 2022 and has since advanced 65%, led by a 130% gain in the technology sector. But equity analyst Dan Ives at Wedbush says the bull market will run for another two to three years, and he believes technology stocks could soar 25% in 2025.
Positive
The Motley Fool
2 weeks ago
3 Unstoppable Growth ETFs to Stock Up On in 2025 and Beyond
Investing in a growth ETF can be a smart way to build your portfolio with minimal effort. A growth ETF is a collection of stocks that have the potential to earn higher-than-average returns, grouped together into a single investment.
Neutral
Business Wire
2 weeks ago
Vergent Bioscience Receives FDA Fast Track Designation for Abenacianine for Injection (VGT-309) to Help Surgeons Visualize Tumors in the Lung During Surgery
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation for the company's novel, investigational tumor-targeted fluorescent imaging agent, abenacianine for injection (VGT-309), as an adjunct for the intraoperative visualization of primary lung cancer, other pulmonary lesions, cancer containing lymph nodes, and positive surgica.
Charts implemented using Lightweight Charts™